Advertisement
Advertisement
U.S. markets close in 21 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9000-0.0700 (-3.55%)
As of 03:37PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close1.9700
Open2.0300
Bid1.9100 x 2900
Ask1.9200 x 1000
Day's Range1.8315 - 2.0300
52 Week Range1.7900 - 6.8400
Volume201,042
Avg. Volume731,504
Market Cap113.898M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.5310
Earnings DateMay 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GMDA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gamida Cell Ltd.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Business Wire

    Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

    BOSTON, June 13, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.

  • Business Wire

    Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

    BOSTON, June 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces the appointment of Ivan M. Borrello, M.D. to its Board of Directors, effective June 9, 2022. Dr. Borrello is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a renowned physician and author who has made major contributions to better

  • Business Wire

    Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

    BOSTON, June 02, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced completion of the rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

Advertisement
Advertisement